We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

37 hedge funds and large institutions have $33.6M invested in Bolt Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $27.1M → $33.6M (+$6.49M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.04% less ownership

Funds ownership: 3.19% → 3.15% (-0.04%)

5% less funds holding

Funds holding: 39 → 37 (-2)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
37
Holders Change
-2
Holders Change %
-5.13%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
8
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$170K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$123K
3
Renaissance Technologies
Renaissance Technologies
New York
+$83.8K
4
AI
Acuitas Investments
Washington
+$67.7K
5
Prudential Financial
Prudential Financial
New Jersey
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$269K
2
Morgan Stanley
Morgan Stanley
New York
-$155K
3
PFMU
Privium Fund Management (UK)
United Kingdom
-$130K
4
Jane Street
Jane Street
New York
-$63K
5
Citadel Advisors
Citadel Advisors
Florida
-$50.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$4.93M – – –
TCM
2
Tang Capital Management
California
$4.79M -$269K -11,612 -6%
SI
3
Sofinnova Investments
California
$3.86M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$3.38M -$50.1K -2,162 -2%
PBPIA
5
Pivotal bioVenture Partners Investment Advisor
California
$2.65M – – –
NM
6
Newtyn Management
New York
$2.38M +$170K +7,323 +9%
O
7
OrbiMed
New York
$2.16M – – –
NFGH
8
Nan Fung Group Holdings
Hong Kong
$1.63M – – –
SB
9
Samsara BioCapital
California
$1.47M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.45M +$123K +5,324 +11%
BOTOTLSJU
11
Board of Trustees of The Leland Stanford Junior University
California
$1.01M – – –
AI
12
Acuitas Investments
Washington
$725K +$67.7K +2,925 +13%
Renaissance Technologies
13
Renaissance Technologies
New York
$725K +$83.8K +3,618 +16%
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
$700K – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$487K -$3.01K -130 -0.7%
BlackRock
16
BlackRock
New York
$357K -$2.69K -116 -0.9%
BCM
17
Bridgeway Capital Management
Texas
$156K – – –
MAM
18
Marquette Asset Management
Minnesota
$135K – – –
Fidelity Investments
19
Fidelity Investments
Massachusetts
$110K -$347 -15 -0.4%
Squarepoint
20
Squarepoint
New York
$109K -$2.04K -88 -2%
State Street
21
State Street
Massachusetts
$66.4K – – –
Millennium Management
22
Millennium Management
New York
$64.3K -$1.2K -52 -2%
Northern Trust
23
Northern Trust
Illinois
$57.4K – – –
Prudential Financial
24
Prudential Financial
New Jersey
$49.3K +$26.6K +1,150 +189%
Morgan Stanley
25
Morgan Stanley
New York
$34.6K -$155K -6,705 -84%
1
2

BOLT Hedge Fund Activity: Q1 2024 in Review

37 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2024, worth a combined $33.6M — up 24% from $27.1M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BOLT and 2 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Newtyn Management, adding an estimated $170K. The largest seller was Tang Capital Management, cutting an estimated $269K.

  • 37 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2024, down from 39 in Q4 2023.
  • Funds reported $33.6M of Bolt Biotherapeutics stock for Q1 2024, up 24% quarter-over-quarter.
  • 2 funds opened new Bolt Biotherapeutics positions in Q1 2024 and 4 closed out, a net change of -2 holders.
  • The largest Bolt Biotherapeutics buyer in Q1 2024 was Newtyn Management, an estimated $170K added.
  • The largest Bolt Biotherapeutics seller in Q1 2024 was Tang Capital Management, an estimated $269K sold.

Based on aggregated 13F filings for Q1 2024.